---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-002009"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2024-01-24T23:59:59+00:00"
generated_at: "2026-06-06T19:23:06.154909+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Abbott Q4 adj EPS $1.19, base organic +11%; FY24 guide $4.50-$4.70

## Summary
- Q4 reported sales $10.241B (+1.5%); organic base business growth +11.0% excluding COVID tests.
- GAAP diluted EPS $0.91; adjusted diluted EPS $1.19. Full-year 2023 adjusted EPS $4.44.
- FY2024 guidance: GAAP EPS $3.20-$3.40, adjusted EPS $4.50-$4.70; organic sales growth 8-10% ex-COVID.
- Medical Devices sales +17.5% reported; FreeStyle Libre revenue $1.4B (+23.8% organic).
- Nutrition sales +12.2% reported, +13.9% organic; U.S. infant formula regained market-leading position.

## SEC filing metadata
- accession: 0001628280-24-002009
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2024-01-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828024002009/0001628280-24-002009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828024002009/abt-20240124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-002009
- JSON: https://secwatch.observer/filing/0001628280-24-002009.json
- Plain text: https://secwatch.observer/filing/0001628280-24-002009.txt

## Key facts
- Earnings Releases
  ABBOTT LABORATORIES reported full-year 2024 results: EPS full-year adjusted diluted EPS of $4.50 to $4.70. Guidance initiated.
  - Period: full-year 2024
  - EPS: full-year adjusted diluted EPS of $4.50 to $4.70
  - Guidance: initiated
  - Result: guidance update
  source text: Abbott issues full-year 2024 guidance for diluted EPS on a GAAP basis of $3.20 to $3.40 and full-year adjusted diluted EPS of $4.50 to $4.70.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800/000162828024002009/0001628280-24-002009-index.htm
- Earnings Releases
  ABBOTT LABORATORIES reported the fourth quarter ended Dec. 31, 2023 results: EPS Fourth-quarter GAAP diluted EPS of $0.91 and adjusted diluted EPS of $1.19. Guidance initiated.
  - Period: the fourth quarter ended Dec. 31, 2023
  - EPS: Fourth-quarter GAAP diluted EPS of $0.91 and adjusted diluted EPS of $1.19
  - Guidance: initiated
  - Result: reported results
  source text: On January 24, 2024, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800/000162828024002009/0001628280-24-002009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.